A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter, double-blinded, adjuvant-controlled trial with two gp120 vaccines in 296 HIV-1-uninfected volunteers, including 176 reporting higher HIV-1 risk activities. The immunogens were remarkably well tolerated. After three immunizations, 210 of 241 vaccinees (87%) developed neutralizing antibodies, which persisted in 59% after 2 years. The injection drug users receiving SF-2/gp120 had decreased antibody responses relative to the lower risk groups. Envelope-specific lymphoproliferation peaked after two immunizations, and 54% of vaccinees mounted a DTH reaction to gp120 after 4 years. In summary, these immunogens have low adverse reactogenicity and induce durable antibody and T cell responses to the prototype strains. Unexpected differences in antibody responses among diverse HIV-1 risk strata lend support to the conduct of expanded phase II trials in populations other than low-risk volunteers.

Full Text

Duke Authors

Cited Authors

  • McElrath, MJ; Corey, L; Montefiori, D; Wolff, M; Schwartz, D; Keefer, M; Belshe, R; Graham, BS; Matthews, T; Wright, P; Gorse, G; Dolin, R; Berman, P; Francis, D; Duliege, AM; Bolognesi, D; Stablein, D; Ketter, N; Fast, P

Published Date

  • June 10, 2000

Published In

Volume / Issue

  • 16 / 9

Start / End Page

  • 907 - 919

PubMed ID

  • 10875616

International Standard Serial Number (ISSN)

  • 0889-2229

Digital Object Identifier (DOI)

  • 10.1089/08892220050042846


  • eng

Conference Location

  • United States